Haim Bio Co., Ltd.

The objectives of this study are:
Part 1:
To assess the MTD, safety and efficacy of each NYH817G and NYH100P in monotherapy in patients with advanced solid tumors who have failed approved standard therapies.
To assess the PK properties and the preliminary effectiveness of monotherapy of NYH817G and NYH100P.
Part 2:
To assess the MTD, RP2D, safety and efficacy of NYH817G and NYH100P in combination therapy in patients with advanced solid tumors who have failed approved standard therapies
To assess the PK properties, the preliminary effectiveness and the changes in metabolism of combination therapy of NYH817G and NYH100P.